|Daily Range||$2.70 - $3.00|
|52-Week Range||$2.41 - $6.40|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||2,102,259|
|Current FY EPS||-$1.26|
Orexigen Therapeutics looks like it has the first game-changing obesity drug on its hands. Here's what you need to know.
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.